Pharmaceutical – IMI Site Wed, 16 Jun 2021 05:43:03 +0000 en-US hourly 1 Pharmaceutical – IMI Site 32 32 CROSSJECT: License agreement in the United States and Canada with Eton Pharmaceuticals for the hydrocortisone ZENEO® by Crossject Wed, 16 Jun 2021 05:32:46 +0000

Press release

License agreement in the United States and Canada
with And we Medicines
for Crossject ZENEO® Hydrocortisone

  • Exclusive license, distribution and promotion agreement in the United States and Canada with Eton
  • Eton focuses on the development and commercialization of innovative pharmaceutical products in endocrinology
  • Pre-market payments to Crossject of US $ 5 million
  • Upon commercial launch, Crossject will supply Eton at a unit price and receive 10% royalty on Eton’s net sales, plus up to US $ 6 million in 3 commercial stages

Dijon, June 15, 2021

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharmaceutical company that is soon developing and will market a portfolio of drug device combinations for use in emergency situations announces the signing of a trade agreement between the United States and Canada.

Patrick Alexandre, CEO of Crossject, said: ”We are proud to announce a strong commercial agreement for ZENEO® Hydrocortisone in the United States and Canada with a United States leader in adrenal insufficiency. Etonne has successfully established solid relationships with patient communities and medical specialists who are at the heart of its concerns. ZENEO® Hydrocortisone meets a medical need. This strong partnership will help save lives by providing patients and their families with a self-injection possibility. ”

Sean Brynjelsen, CEO of Eton Pharmaceuticals, said: ”the ZENEO® auto-injector is a revolutionary delivery system and this product fits perfectly into our current adrenal insufficiency business. Patients, advocacy groups and physicians in the adrenal insufficiency community have repeatedly expressed the need for hydrocortisone to us. auto-injector, so we are delighted to partner with Crossject bring this product to patients in need.

A solid trade agreement on a key geography

Crossject and Eton Pharmaceuticals have signed an agreement for ZENEO® Hydrocortisone in the United States and Canada. Under this agreement, Eton will be responsible for all regulatory and commercial activities, including licensing, regulatory filing fees, distribution and promotion. The agreement covers the United States and Canada, a geographic area with strong market potential. Crossject will be responsible for the management and expenses of development, clinical and manufacturing activities.

The agreement includes:

  • Until the marketing authorizations are granted: development and regulatory milestones of 5 M USD, of which 0.5 M USD paid to CROSSJECT upon signing and 0.5 M USD sequestered; the other milestones are expected over the next 3 years;
  • Crossject will receive (i) a double-digit average price for each ZENEO® Hydrocortisone supplied to Eton; and (ii) 10% royalty based on Eton’s net sales; and (iii) sales milestones of up to US $ 6 million subject to Eton’s 3 annual net sales thresholds.

ZENEO® Hydrocortisone, an answer to an unmet medical need

The ready-to-use ZENEO® Hydrocortisone will provide a 2-step rescue kit developed for simple and intuitive self-injection even by non-healthcare professionals.

Adrenal crisis, also known as acute adrenal insufficiency, is a rare, life-threatening medical condition requiring immediate emergency treatment. Patients and caregivers are currently trained by healthcare professionals to use a 15-step first aid kit before starting the injection. ZENEO® Hydrocortisone will provide an easy to use and rapid first aid kit for patients and their caregivers.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for rare pediatric diseases. Eton currently owns or receives royalties from three FDA-approved products, including ALKINDI SPRINKLE®, a corticosteroid with orphan drug status indicated as replacement therapy in pediatric patients with adrenal insufficiency, Biorphen® and Alaway Preservative Free®, and submitted six other products to the FDA.



Crossject (ISIN: FR0011716265; Mnemonic: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and will soon market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from financing from Bpifrance

  • US-Canada License Agreement with Eton Pharmaceuticals_VENG

Source link

]]> 0
Is it too late to buy Vertex Pharmaceuticals shares? Tue, 15 Jun 2021 09:40:00 +0000

Vertex Pharmaceutical (NASDAQ: VRTX) is a biotechnology that focuses on the treatment of rare diseases. Its stock has significantly underperformed over the past year after soaring, falling almost 36% from its July highs.

It is the company that developed the only pharmaceutical treatments for cystic fibrosis (CF), a genetic disease that causes persistent lung infections. Vertex had been very successful in combating the disease and bringing its drugs to market. So what went wrong?

Image source: Getty Images.

What happened?

On June 11, Vertex shares fell 10% in a single day after the company halted development of VX-864, a drug being investigated for the treatment of a liver disease called alpha-deficiency. 1 antitrypsin (AATD). Although VX-864 met the primary endpoint in Phase 2, the researchers did not believe this would translate into any significant clinical benefit. Last October, Vertex dropped another candidate, VX-814, for the same condition. The company reinvested 26% of its sales each quarter in research and development, so the failure was quite disappointing.

That leaves only CTX001, a gene therapy for the treatment of inherited blood disorders, as the primary candidate in the pipeline. However, Vertex is developing transfusion therapy in conjunction with CRISPR Therapeutics (NASDAQ: CRSP). In addition to the profit-sharing agreements, Vertex has already paid the latter $ 900 million to jointly develop the technology. So even after approval, it still has a long way to go to break even.

Can you still count on Vertex?

From an investment standpoint, the biggest problem with Vertex is that it is too dependent on its triple combination cystic fibrosis treatment Trikafta, which was approved in October 2019. In clinical studies, Trikafta has shown 10% to 13% benefit in improving patients. lung function, improved their quality of life and body mass index, and provided respiratory relief. However, these benefits come at a staggering cost of $ 311,000 per year.

There are only about 83,000 patients with cystic fibrosis in developed countries. Almost half of them are already taking Vertex drugs. It’s safe to say that the company has hit a brick wall in terms of generating prescription volume due to its pricing.

In the first quarter of 2021, the company’s revenue grew only 14% year-on-year to $ 1.4 billion. Meanwhile, its net profit grew 16% year-over-year to $ 781 million. Keep in mind that Vertex posted 77% revenue growth and 128% profit growth in the first quarter of 2020 compared to the first quarter of 2019.

This is all problematic, as Vertex stock is currently trading at 8x earnings and 19x earnings. Without the launch of new pipeline candidates, it cannot maintain these valuation levels. I think there is more fighting ahead for his actions. It’s best to avoid biotechnology for now.

This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are heterogeneous! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.

Source link

]]> 0
US FDA refuses to approve Avenue’s IV formulation of non-opioid pain relievers Mon, 14 Jun 2021 16:39:00 +0000

Signage is seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, USA, August 29, 2020. REUTERS / Andrew Kelly / File Photo

Avenue Therapeutics Inc (ATXI.O) said on Monday that the United States Food and Drug Administration (FDA) had refused to approve its intravenous formulation of the non-opioid pain reliever tramadol for the second time, dropping its shares by approximately 38%.

The FDA has pushed drugmakers to develop alternatives to opioid-based pain relievers as the United States grapples with the threat of opioid addiction.

The health regulator in October refused to approve the intravenous formulation of the pain reliever, saying it was not safe for the target population.

The agency said Monday that the delayed and unpredictable onset of analgesia – pain relief – with intravenous (IV) tramadol did not support its benefit as monotherapy to treat patients with acute pain.

There was also not enough data to support that IV tramadol was safe and effective in combination with other drugs, the FDA said in its decision made more than two months after the scheduled April 12 date.

HC Wainwright analyst Joseph Pantginis, however, says tramadol IV may still have a way to go.

The FDA did not mention any “chemistry, manufacturing and controls (CMC)” issues in its full response letter, Avenue said, adding that it disagreed with the agency’s decision and would continue. seek regulatory approval for tramadol IV.

Tramadol was approved in the United States in 1995 as an uncontrolled pain reliever, under the trade name Ultram, for sale by drug maker Johnson & Johnson (JNJ.N).

Our Standards: The Thomson Reuters Trust Principles.

Source link

]]> 0
Hedge funds in standby mode Sun, 13 Jun 2021 22:13:46 +0000

Last year, we predicted the onset of the first US recession since 2009 and we predicted in advance that the market would decline by at least 20% in (Recession is looming: we need a travel ban NOW). In these volatile markets, we take a close look at hedge fund deposits to get a reading of the direction each stock might take. In this article, we’ll take a closer look at hedge fund sentiment towards Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN).

Interest of hedge funds in Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) shares was stable at the end of the last quarter. This is usually a negative indicator. Our calculations also showed that DFFN is not in the top 30 most popular stocks among hedge funds (click for Q1 rank). At the end of this article, we’ll also be comparing DFFN to other stocks, including Core Molding Technologies, Inc. (NYSE: CMT), Sino-Global Shipping America, Ltd. (NASDAQ: SINO) and Acasti Pharma Inc. (NASDAQ: ACST) to get a better idea of ​​its popularity.

In today’s market, there are many signals that market participants use to value their investments in stocks. Some of the lesser used signals are hedge fund and insider trading signals. Our researchers have shown that, historically, those who follow the best picks of elite fund managers can beat the S&P 500 by a significant amount (see details here). Additionally, our monthly newsletter’s long stock picks portfolio has returned 206.8% since March 2017 (through May 2021) and has beaten the S&P 500 Index by over 115 percentage points. You can download a sample issue of this newsletter from our website.

John Overdeck of Two Sigma

John Overdeck of Two Sigma Advisors

At Insider Monkey, we scour multiple sources to uncover the next big investing idea. For example, an activist hedge fund wants to buy this biotech share at $ 26 for $ 50. We therefore recommended a long position to our monthly premium newsletter subscribers. We’re going through lists like the top 10 battery stocks to pick the next Tesla that will deliver 10x performance. Even though we only recommend positions in a tiny fraction of the companies we analyze, we check as many stocks as possible. We read letters from hedge fund investors and listen to equity pitches at hedge fund conferences. You can sign up for our free daily newsletter on our homepage. With all of that in mind, let’s take a look at the new hedge fund action encompassing Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN).

Do hedge funds think DFFN is a good stock to buy now?

At the end of the first quarter, a total of 3 of the hedge funds tracked by Insider Monkey were long in this stock, a change of 0% from the previous quarter. On the other hand, there were a total of 4 hedge funds with a bullish position on DFFN a year ago. With the whirlwind of hedge fund sentiment, there is a select group of key hedge fund managers who were significantly increasing their holdings (or already building up large positions).

The largest stake in Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) was held by Renaissance Technologies, which said it held $ 1.7 million in shares at the end of December. It was followed by Millennium Management with a position of $ 0.3 million. The only other hedge fund that is bullish on the company was Two Sigma Advisors.

We believe that hedge fund activity on the stock is unfavorable, but in this case there was only one hedge fund that sold its entire position: Citadel Investment Group. A hedge fund that sells its entire position does not always imply a bearish intention. Theoretically, a hedge fund can decide to sell a promising position in order to invest the proceeds in a more promising idea. However, we do not believe this to be the case in this case, as only one of the 800+ hedge funds tracked by Insider Monkey identified itself as a viable investment and initiated a position in the stock (this fund was Millennium Management ).

Let’s review hedge fund activity in other stocks similar to Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN). These stocks are Core Molding Technologies, Inc. (NYSE: CMT), Sino-Global Shipping America, Ltd. (NASDAQ: SINO), Acasti Pharma Inc. (NASDAQ: ACST), Document Security Systems, Inc. (NYSE: DSS), SilverBow Resorces, Inc. (NYSE: SBOW), Cortland Bancorp (NASDAQ: CLDB) and NexPoint Real Estate Finance, Inc. (NYSE: NREF). The market value of this group of shares is similar to the market value of DFFN.

[table] Ticker, number of HF with positions, total value of HF positions (x1000), change of HF position CMT, 3,17252, -1 SINO, 1,169,1 ACST, 1,31, -3 DSS, 2,294,1 SBOW, 4 , 36762, -2 CLDB, 2.9927.0 NREF, 2.3997, -2 Medium, 2.1.9776, -0.9 [/table]

Check the table here if you have formatting issues.

As you can see, these stocks had an average of 2.1 hedge funds with bullish positions and the average amount invested in these stocks was $ 10 million. That figure was $ 2 million in the case of DFFN. SilverBow Resorces, Inc. (NYSE: SBOW) is the most popular share in this table. On the other hand, Sino-Global Shipping America, Ltd. (NASDAQ: SINO) is the least popular with only 1 bullish hedge fund positions. Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) isn’t the most popular stock in this group, but hedge fund interest is still above average. Our overall hedge fund sentiment score for DFFN is 60.8. Stocks with a higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. This is a slightly positive signal, but we prefer to spend our time researching the stocks on which hedge funds are accumulating. Our calculations showed that the 5 most popular stocks among hedge funds returned 95.8% in 2019 and 2020 and outperformed the S&P 500 ETF (SPY) by 40 percentage points. These stocks gained 17.2% in 2021 through June 11 and again beat the market by 3.3 percentage points. Unfortunately, DFFN was not as popular as these 5 stocks and the hedge funds that bet on DFFN were disappointed as the stock has returned -14.1% since the end of March (until 6/11) and has under- performed the market. If you want to invest in large cap stocks with huge upside potential, you should check out the 5 most popular stocks among hedge funds, as many of these stocks have already outperformed the market since 2019.

Receive real-time email alerts: Follow Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)

Disclosure: none. This article originally appeared on Insider Monkey.

Related content

Source link

]]> 0
The pharmaceutical industry, the global helping hand: Ch. Muhammad Israr Sharif, MD and CEO Genix Pharma PVT LTD – Supplements Sat, 12 Jun 2021 22:56:37 +0000

TEXT: The pharmaceutical industry in Pakistan is growing at a rapid pace, contributing significantly to the national economy, although the current pandemic situation has hit the world very hard, COVID -19 has put unprecedented pressure on the systems health of each nation. But the Pakistani pharmaceutical industry plays a critical role in ensuring access to essential medicines and health care services.

Pakistan’s pharmaceutical and healthcare industries are very competitive and stimulating. There are nearly 700 pharmaceutical companies operating in Pakistan, with the main world leaders present in the country, with regulatory and pricing issues at the top of the list. The industry presents many growth opportunities for drug manufacturers as the opportunities are driven by the increasing burden of chronic disease, which is the fastest growing segment in the current scenario.

Genix | A formula for success

Genix Pharma. Founded in 2004, the company was conceived by the late Choudhry Muhammad Sharif Sahib, who made it his mission to provide top quality and affordable medicines to all who need them.

Since then, Genix has grown into one of the fastest growing companies in the Pakistani pharmaceutical arena and a rising force in the international market. In recent years, it has achieved phenomenal export penetration in the markets of Southeast Asia, South and Central Asia and several regions of Africa.

Genix has a skilled workforce of employees through a combination of its own dedicated sales force and nationwide third-party distribution infrastructure.

Its success is also in part attributable to the belief of its current Managing Director and CEO Choudhry Muhammad Israr Sharif in the power of marketing and its competence in its execution. “It has been a long but successful journey which owes a lot to teamwork and our focus on quality and branding from day one.” We believe in selling branded products rather than individual products. These brands nonetheless rely on the quality of the basic product.

And the staff of Genix Pharma. High-tech factories and advanced and well-equipped quality laboratories are determined to make the company the benchmark of the Pakistani pharmaceutical industry. “

With this goal in mind, Genix regularly launches revolutionary products.

Genix pharma has a state-of-the-art quality control laboratory with highly specialized equipment compliant with FDA 21 CFR standards for the testing and analysis of various products and materials.

Genix also understands the importance of corporate social responsibility (CSR). The company contributes to the humanitarian and social activities of businesses through charitable donations such as funding for education, donations in the health sector and the organization of food for the poor and needy.

“Genix is ​​dedicated to the good health of all human beings by providing advanced quality drugs in various diverse therapeutic segments around the world”, “We continue to invest in our brands today, because we believe that tomorrow is too late.” Surely a mantra for continued growth and success.

Genix | Pharma nationwide

One of the main reasons for Genix Pharma’s success is its strong nationwide distribution network throughout Pakistan. With our trusted distributors located throughout, ensuring uninterrupted availability of Genix Pharma products during the pandemic situation in all regions of the country.

Compiling with our goal of providing quality medicines within reach of all those in urgent need with the lowest possible prices and improved standards, we have maintained long-term relationships with our valued business partners.

Genix | Global pharmaceutical presence

Genix aspires to be one of the world’s most respected, dynamic and integrated pharmaceutical companies with the vision of expanding the horizon for “Global Care”. Over the past few years, Genix has experienced phenomenal growth in international markets, starting with exports to developing markets in Southeast Asia, South Asia, Central Asia, Gulf countries , East Africa, West Africa and French-speaking Africa. We are strengthening and expanding our direct presence in emerging markets and establishing strategic partnerships in the rest of the world.

Copyright Business Recorder, 2021

Source link

]]> 0
These 4 metrics indicate that Zhongzhi Pharmaceutical Holdings (HKG: 3737) is using debt reasonably well Sat, 12 Jun 2021 01:38:20 +0000

Warren Buffett said: “Volatility is far from synonymous with risk”. So it can be obvious that you need to consider debt, when you think about how risky a given stock is because too much debt can sink a business. Like many other companies Zhongzhi Pharmaceutical Holdings Limited (HKG: 3737) uses debt. But the real question is whether this debt makes the business risky.

Why Does Debt Bring Risk?

Debt is a tool to help businesses grow, but if a business is unable to repay its lenders, then it exists at their mercy. Ultimately, if the company cannot meet its legal debt repayment obligations, shareholders could walk away with nothing. However, a more common (but still costly) situation is where a company has to dilute its shareholders at a cheap share price just to get its debt under control. Of course, many companies use debt to finance their growth without negative consequences. The first step in examining a company’s debt levels is to consider its cash flow and debt together.

Check out our latest review for Zhongzhi Pharmaceutical Holdings

What is the debt of Zhongzhi Pharmaceutical Holdings?

As you can see below, at the end of December 2020, Zhongzhi Pharmaceutical Holdings had a debt of CNN 78.9 million, up from CNN 31.4 million a year ago. Click on the image for more details. However, his balance sheet shows that he has CN ¥ 311.0 million in cash, so he actually has CN ¥ 232.1 million in net cash.

SEHK: 3737 History of debt to equity June 12, 2021

A look at the liabilities of Zhongzhi Pharmaceutical Holdings

The latest balance sheet data shows Zhongzhi Pharmaceutical Holdings had CN 485.5 million liabilities due within one year and CN 113.3 million liabilities due after that. In return, he had CN 311.0 million in cash and CN 285.3 million in receivables due within 12 months. These liquid assets therefore correspond roughly to the total liabilities.

This fact indicates that Zhongzhi Pharmaceutical Holdings’ balance sheet looks quite strong, as its total liabilities roughly equal its liquid assets. So while it’s hard to imagine the CN 996.5 million company struggling to find the money, we still think it’s worth watching its balance sheet. While he has some liabilities to note, Zhongzhi Pharmaceutical Holdings also has more cash than debt, so we’re pretty confident that he can handle his debt safely.

The good news is that Zhongzhi Pharmaceutical Holdings increased its EBIT by 8.3% year-over-year, which should allay concerns about debt repayment. The balance sheet is clearly the area you need to focus on when analyzing debt. But it is Zhongzhi Pharmaceutical Holdings’ earnings that will influence the balance sheet in the future. So if you want to know more about its profits, it might be worth checking out this long term profit trend chart.

Finally, a business can only repay its debts with hard cash, not with book profits. Although Zhongzhi Pharmaceutical Holdings has net cash on its balance sheet, it is still worth examining its ability to convert earnings before interest and taxes (EBIT) into free cash flow, to help us understand how fast it is building. (or erode) that cash balance. In the past three years, Zhongzhi Pharmaceutical Holdings has recorded free cash flow of 22% of its EBIT, which is lower than expected. It’s not great when it comes to paying down debt.

In summary

We could understand if investors are worried about Zhongzhi Pharmaceutical Holdings’ liabilities, but we can be reassured that it has net cash of CND 232.1 million. In addition, it has increased its EBIT by 8.3% over the past twelve months. So we have no problem with the use of debt by Zhongzhi Pharmaceutical Holdings. When analyzing debt levels, the balance sheet is the obvious starting point. However, not all investment risks lie on the balance sheet – far from it. These risks can be difficult to spot. Every business has them, and we’ve spotted 2 warning signs for Zhongzhi Pharmaceutical Holdings (1 of which is potentially serious!) that you should be aware of.

At the end of the day, it’s often best to focus on businesses with no net debt. You can access our special list of these companies (all with a history of profit growth). It’s free.

When trading stocks or any other investment, use the platform considered by many to be the gateway for professionals to the global market, Interactive Brokers. You get the cheapest * trading on stocks, options, futures, forex, bonds and funds from around the world from a single integrated account.

This Simply Wall St article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.
*Interactive Brokers Ranked Least Expensive Broker By Online Annual Review 2020

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)

Source link

]]> 0
Global Botanical Medicines Market Research Report 2021 Analysis – Buchang Pharmaceuticals, China TCM, Tsumura, Schwabe – The Manomet Current Fri, 11 Jun 2021 09:37:32 +0000

A recent comprehensive market research report titled Global Botanical Medicines Market Growth (Status and Outlook) 2021-2026 announced by is an informative representation of current market developments. The report has gained wide acceptance in the industry due to the beneficial features it offers, such as reliability, number accuracy, plain language, etc. The report combines a comprehensive analysis of the markets with a fresh approach to the target industry. The research mainly focuses on current developments, new possibilities, advancements, as well as dormant traps. It provides a record of the Global Botanical Medicines Market report that presents a descriptive analysis of this market research.

The global Botanical Drugs market size, drivers and vulnerabilities, major players, overview of segments, and geographic outlook are among the variables covered in the study. The report involves in-depth analysis of current market dynamics along with past statistics. The report includes data on the business environment, value / volume results, marketing tactics and expert views. Market segmentation provides the client with a comprehensive overview of the entire industry, helping them to make critical decisions in terms of growing their business. Then, the study also provides a credible estimate for the planned period.

NOTE: COVID-19 has a significant impact on businesses and the global economy in addition to serious public health implications. As the pandemic continues to evolve, there is a serious need for businesses to rethink and reconfigure their work packages for the changed world. Many industries around the world have successfully implemented management plans specifically for this crisis. This report gives you a detailed study of the impact of COVID-19 on the Botanical Drug market so that you can build your strategies.


The report integrates company profiles, specifications, product photos, capacity, price, expense, revenue, growth, and contact details of global major industry players in the global Botanical Drug Market. This report then helps to identify the drivers, constraints, threats and opportunities specific to a segment. The market report has four major sections including Competitor section, Merchandise Type Fragment, End Use / Application, and Geographic Fragment.

Major Manufacturers / Key Players / Economy by CEOs of Major Market Players are:

Buchang Pharmaceuticals, China TCM, Tsumura, Schwabe, Tong Ren Tang, Jumpcan Pharmaceutical, Guangzhou Baiyunshan Pharmaceutical, Yunnan Baiyao, Tasly Holding Group, Bionorica Se, Huarun 999, Taiji, Weleda, Kwangdong, GW Pharmaceuticals,

On the basis of product segment, this report covers:

Prescription drug, over-the-counter,

Based on application segment, this report covers:

Cardiovascular, Tumor, Respiratory system, Other

What more in the report?

The report keeps track of recent updates and critical business methods that help the company as well as the companies operating within. In addition, it provides in-depth analysis of their new mergers, investors, stakeholders and acquisitions. This study groups the export markets for products and services in the global botanical drugs market into three categories: strategic, dynamic growth, and long-term opportunity. In addition, a feasibility study of new projects over the forecast horizon is also presented.

Geographically, this report studies the market share and growth opportunities in the following key regions:

Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, United Kingdom, Italy, Russia), Middle East and Africa (Egypt, South Africa, Israel, Turkey, GCC countries)


A desirable feature of the industry report:

  • In-depth analysis based on market segments will enhance the growth of the Global Botanical Medicines Market
  • Analysis of key market players and their trading tactics is highlighted
  • Market technological advancements will fuel global market growth
  • The region-wise analysis and the analysis of emerging market segments will provide a clear view of the global market

Customization of the report:

This report can be customized to meet customer requirements. Please connect with our sales team (, who will make sure you get a report that matches your needs. You can also contact our leaders at + 1-201-465-4211 to share your research needs.

Contact us
Brand Pierre
Head of Business Development
Call: + 1-201-465-4211
The Web:

Source link

]]> 0
Pharmaceutical Executive® unveils 21st annual Pharma 50 Thu, 10 Jun 2021 15:52:00 +0000

“With the end of the COVID-19 pandemic in sight, the Pharmaceutical executive® The Pharma 50 list shows the top sellers who have played a role in addressing the public health crisis facing the industry, ”said Mike Hennessy Jr., President and CEO of MJH Life Sciences ™, parent company of Pharmaceutical executive®. “Although the Pharma 50 has provided an intuitive overview of the industry’s top 50 biopharmaceutical companies for more than 20 years, the companies have recognized that this year faces an even greater challenge due to the pandemic. research, awareness and education, they have played at the highest level. “

In addition to paying particular attention to current connected trends, Pharmaceutical executive® based its ranking of the world’s top 50 biopharmacy leaders on the companies’ annual prescription drug sales in 2020. Data for the list is provided in partnership with life science marketing intelligence firm Evaluate Ltd. top-selling products and their total research and development (R&D) spending.

Roche, which generated $ 47.5 billion in prescription drug sales, ranked first for the second year in a row. Avastin remains the company’s best-selling drug with $ 5.3 billion in 2020 sales. Roche, which was also the first investor in biopharma R&D after investing $ 11.3 billion, has 19 compounds in Phase III clinical trials or submitted for approval.

Novartis ranks second in prescription drug sales, ranking second for the second year in a row and up 2.4% to $ 47.2 billion of the previous year. To complete the top 5 of the Pharma 50, AbbVie, which moved from eighth place in 2020 to third; Johnson & Johnson with 7.7% growth in prescription drug revenue, pushing it up two places to fourth; and Bristol Myers Squibb, which reclaims fifth place with a 3% increase in sales of prescription drugs to $ 41.9 billion.

To view the full list of Pharma 50s, click here.

About Pharmaceutical executive®
Pharmaceutical Director® is a multimedia platform that offers news, opinions, analysis, features and executive profiles. The magazine and its website serve as a forum for industry leaders to exchange opinions, experiences and ideas on innovative business and marketing ideas, strategies and tactics. Pharmaceutical executive® is a trademark of MJH Life Sciences™, the largest private, independent, full-service medical media company in North America, dedicated to disseminating reliable healthcare information across multiple channels.

Pharmaceutical executive® Media contact
Alexandra Ventura, 609-716-7777
[email protected]

SOURCE Pharmaceutical Executive®

Source link

]]> 0
Would shareholders who bought the Hansoh Pharmaceutical Group stock year (HKG: 3692) be happy with the share price today? Thu, 10 Jun 2021 00:27:37 +0000

The easiest way to profit from a bull market is to buy an index fund. When you buy individual stocks, you may realize higher profits, but you also run the risk of underperformance. This downside risk was realized by Hansoh Pharmaceutical Group Company Limited (HKG: 3692) shareholders in the past year, with the share price falling 11%. This is disappointing considering that the market returned 27%. Pharmaceutical group Hansoh may have better days ahead, of course; we only looked at a one-year period. Unfortunately, the stock price fell 5.0% last week.

See our latest analysis for Hansoh Pharmaceutical Group

While the markets are a powerful pricing mechanism, stock prices reflect investor sentiment, not just the underlying performance of the company. A flawed but reasonable way to gauge how sentiment is changing around a company is to compare earnings per share (EPS) with the stock price.

Unfortunately, Hansoh Pharmaceutical Group had to report a 6.3% drop in its BPA over the past year. This drop in EPS is not as bad as the stock price drop of 11%. This suggests that the fall in BPA made some shareholders more nervous about the company. Of course, with a P / E ratio of 61.32, the market remains bullish.

The image below shows how EPS has tracked over time (if you click on the image you can see more detail).

SEHK: 3,692 Growth in earnings per share on June 10, 2021

Dive deeper into key Hansoh Pharmaceutical Group metrics by viewing this interactive Hansoh Pharmaceutical Group earnings, revenue and cash flow chart.

A different perspective

While Hansoh Pharmaceutical Group shareholders are down 11% on the year (including dividends), the market itself is up 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. With the stock down 8.7% in the past three months, the market doesn’t seem to believe the company has solved all of its problems. Given the relatively short history of this stock, we would remain fairly cautious until we see strong trading performance. Is Hansoh Pharmaceutical Group cheap compared to other companies? These 3 evaluation measures could help you decide.

But beware : Hansoh Pharmaceutical Group may not be the best stock to buy. So take a look at this free list of interesting companies with past earnings growth (and new growth forecasts).

Please note that the market returns quoted in this article reflect the market-weighted average returns of stocks currently trading on the Hong Kong stock exchanges.

When trading stocks or any other investment, use the platform considered by many to be the gateway for professionals to the global market, Interactive Brokers. You get the cheapest * transactions in stocks, options, futures, forex, bonds and funds from around the world from one integrated account.

This Simply Wall St article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in the mentioned stocks.
*Interactive Brokers Ranked Least Expensive Broker By Online Annual Review 2020

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)

Source link

]]> 0
Sulfadimethoxine (SDM) market size and growth 2021-2027 Wed, 09 Jun 2021 03:00:18 +0000

Sulfadimethoxine (SDM) Market is created in this intelligence report. This comprehensive research report is a well-thought compilation of detailed development and growth factors of the market optimizing the path for continued growth in terms of exact product data, strategies and market share of the leading companies in this market. particular. We follow an iterative model of research methodology to formulate the report which helps decision makers make an informed investment assessment. Literature research is conducted using internal and external sources to obtain qualitative and quantitative market information supported by primary research.

Huge data and knowledge about the credible Sulfadimethoxin (SDM) market report has been gathered from various reliable sources such as journals, websites, white papers, company annual reports, and mergers. This market research report can be a great solution to help you make better decisions, earn maximum income, and improve your business profits. This market research report offers a systematic idea of ​​the current scenario of the global market. Recent developments, product launches, joint ventures, capacities, production values, mergers and acquisitions have supported various market dynamics. Comprehensive Sulfadimethoxine (SDM) market research report not only offers an opportunity to outlast the competition, but also to outperform the competition.

The research report included the profiles of top sellers of the company’s competitors, their data, revenue, revenue share, business volume and buyer volume. This statistical survey report has also examined the factors influencing key industry players in the adoption of the synthetic sourcing products market. The conclusions contained in this report are of great value to the major players in the industry. This report has mentioned all the organizations involved in the global production of the Sulfadimethoxine (SDM) market products to study the information relating to low-cost manufacturing methods, competitive conditions, and new uses. The report is based on monitoring market performance since 2015 and is one of the most detailed reports

The report covers the following key players in the Sulfadimethoxine (SDM) market:

• Tianhe pharmaceutical
• Jiuzhou Pharma
• Zhejiang Chemsyn Pharm
• Nanhai Beisha pharmaceutical
• Novachems

Sulfadimethoxine (SDM) market segmentation:

By Product Type, the market is primarily split into:

• 98%
• 98%

By application, this report covers the following segments:

• Drug
• Other

Scope of Sulfadimethoxin (SDM) Market Report

Report attribute Details
Market size available for years 2021 – 2027
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2027
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of the report (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of personalized shopping options to meet your exact research needs. Explore purchasing options

Sulfadimethoxine (SDM) Geographic Market Analysis:

The latest business intelligence report analyzes the Sulfadimethoxine (SDM) market in terms of market scope and customer base in the major geographies of the market. The Sulfadimethoxine (SDM) market can be geographically divided into North America, Asia-Pacific, Europe, Latin America, Middle East and Africa. This section of the report provides an accurate assessment of the Sulfadimethoxin (SDM) market presence in major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

The Sulfadimethoxine (SDM) Market report provides information on the following pointers:

  1. Market penetration: Complete information on the product portfolios of the major players in the Sulfadimethoxin (SDM) market.
  2. Product Development / Innovation: Detailed information on upcoming technologies, R&D activities and product launches in the market.
  3. Competitive assessment: In-depth assessment of market strategies, geographic and business segments of key market players.
  4. Market development: Comprehensive information on emerging markets. This report analyzes the market for various segments across geographies.
  5. Market diversification: Comprehensive information about new products, untapped geographies, recent developments and investments in the Sulfadimethoxine (SDM) market.

Visualize Sulfadimethoxine (SDM) Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for narrative storytelling for this market. VMI offers in-depth forecasting trends and accurate insights into over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a holistic overview and global competitive landscape with regard to region, country and segment, and key players in your market. Present your market report and findings with a built-in presentation function, saving over 70% of your time and resources for investor arguments, sales and marketing, R&D and product development. VMI enables data delivery in interactive Excel and PDF formats with over 15+ key market indicators for your market.

How Will This Market Intelligence Report Help You?

  1. The report offers statistical data in terms of value (US $) as well as volume (units) through 2027.
  2. An exclusive overview of key trends affecting the Sulfadimethoxine (SDM) industry, although key threats, opportunities, and disruptive technologies may shape the global Sulfadimethoxine (SDM) market supply and demand.
  3. The report follows the key market players that will shape and have the greatest impact in the global Sulfadimethoxine (SDM) market.
  4. The analysis of the data presented in the Sulfadimethoxine (SDM) report is based on the combination of primary and secondary resources.
  5. The report helps you to understand the actual effects of major market drivers or retention agents on Sulfadimethoxine (SDM) business.

Why is the Sulfadimethoxin (SDM) Market Report Beneficial?

  • The Sulfadimethoxin (SDM) report is compiled with in-depth and dynamic research methodology.
  • The report offers a complete picture of the Sulfadimethoxine (SDM) market competitive scenario.
  • It includes a large amount of information on the latest technologies and product developments in the sulfadimethoxine (SDM) industry.
  • The wide range of assays is associated with the impact of these improvements on the future growth of the Sulfadimethoxine (SDM) industry.
  • The Sulfadimethoxin (SDM) report combined the essential historical data and analysis required into the comprehensive research report.
  • The information in the Sulfadimethoxin (SDM) report can be easily understood and contains a graphical representation of the numbers in the form of bar charts, statistics and pie charts etc.

About us: verified market reports

Verified Market Reports is a leading global research and advisory firm serving more than 5,000 clients around the world. We provide advanced analytical research solutions while delivering insightful research studies.

We also provide insight into the analytics and strategic and growth data needed to achieve business goals and critical revenue decisions.

Our 250 analysts and SMEs offer a high level of expertise in data collection and governance using industry techniques to collect and analyze data on more than 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Our research covers a multitude of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage, and more. Having served numerous Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768


Website: –

Source link

]]> 0